Previous 10 | Next 10 |
MINNEAPOLIS, MN / ACCESSWIRE / February 1, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into pioneering diagnostics and expanded therapeutic options for cancer patients, announced that it will release its financial...
- Trial will evaluate the efficacy and safety of Pfizer’s targeted therapies, VIZIMPRO ® and XALKORI ® , in patients with metastatic HER2-negative breast cancer selected by Celcuity’s CELsignia Multi-Pathway Activity Test - First clinical trial to tre...
Celcuity Inc. (Nasdaq: CELC), a clinical stage biotechnology company utilizing its 3 rd generation companion diagnostics to identify new targeted therapeutic options for cancer patients, announced today that Brian Sullivan, Chairman, Chief Executive Officer, and Co-Founder of Celcui...
Celcuity (CELC) announces a clinical trial collaboration with Massachusetts General Hospital and Puma Biotechnology ((PUMA)), a biopharmaceutical company, to conduct a Phase II clinical trial.The study will evaluate the efficacy and safety of Puma's NERLYNX and FASLODEX in meta...
- UCLA Jonsson Comprehensive Cancer Center and Vanderbilt-Ingram Cancer Center will also participate - Study will evaluate the efficacy and safety of NERLYNX® and FASLODEX® in metastatic HR-positive, HER2-negative breast cancer patients selected by the CELsignia® Test ...
Celcuity Inc. (CELC) Q3 2020 Earnings Conference Call November 9, 2020 4:30 p.m. ET Company Participants Vicky Hahne - CFO Brian Sullivan - CEO Conference Call Participants Boobalan Pachaiyappan - H.C. Wainwright Alex Nowak - Craig-Hallum Capital Presentation Operator Good day, everyone, and ...
-New clinical trial collaborations with pharmaceutical companies on track to close -Cash burn rate steady -Cash and cash equivalents of $13.7 million as of September 30, 2020, which is expected to support operations through 2021 -Conference Call on Monday, November 9th at 4:30...
MINNEAPOLIS, MN / ACCESSWIRE / October 26, 2020 / Celcuity Inc. (Nasdaq:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into pioneering diagnostics and expanded therapeutic options for cancer patients, announced that it will release its financial...
MINNEAPOLIS, MN / ACCESSWIRE / August 27, 2020 / Celcuity Inc. (NASDAQ:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into pioneering diagnostics and expanded therapeutic options for cancer patients, announced today that management will present ...
Start Time: 16:30 End Time: 16:47 Celcuity Inc. (CELC) Q2 2020 Earnings Conference Call August 10, 2020, 16:30 PM ET Company Participants Brian Sullivan - Co-Founder and CEO Vicky Hahne - CFO Conference Call Participants Boobalan Pachaiyappan - H.C. Wainwright William F...
News, Short Squeeze, Breakout and More Instantly...
2024-07-10 10:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
MINNEAPOLIS, June 03, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Jefferies Global Healthcare Conference to be held in New York on June 4-6, 2024. ...
2024-05-30 16:00:09 ET Bradley Canino from Stifel Nicolaus issued a price target of $40.00 for CELC on 2024-05-30 14:29:00. The adjusted price target was set to $40.00. At the time of the announcement, CELC was trading at $15.28. The overall price target consensus is at ...